← All trials
NCT06411314
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 29, 2022
- Primary completion
- Jul 26, 2023
- Completion date
- Sep 22, 2023
- First posted
- May 13, 2024
- Last posted
- May 13, 2024
- Enrollment
- 218
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Avva Rus, JSCLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.